Breuleux M - Search Results

1

Optimal targeting of the mTORC1 kinase in human cancer.

Lane HA, Breuleux M. Lane HA, et al. Among authors: breuleux m. Curr Opin Cell Biol. 2009 Apr;21(2):219-29. doi: 10.1016/j.ceb.2009.01.016. Epub 2009 Feb 21. Curr Opin Cell Biol. 2009. PMID: 19233631 Review.

2

The Ret receptor tyrosine kinase pathway functionally interacts with the ERalpha pathway in breast cancer.

Boulay A, Breuleux M, Stephan C, Fux C, Brisken C, Fiche M, Wartmann M, Stumm M, Lane HA, Hynes NE. Boulay A, et al. Among authors: breuleux m. Cancer Res. 2008 May 15;68(10):3743-51. doi: 10.1158/0008-5472.CAN-07-5100. Cancer Res. 2008. PMID: 18483257 Free article.

3

Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition.

Breuleux M, Klopfenstein M, Stephan C, Doughty CA, Barys L, Maira SM, Kwiatkowski D, Lane HA. Breuleux M, et al. Mol Cancer Ther. 2009 Apr;8(4):742-53. doi: 10.1158/1535-7163.MCT-08-0668. Mol Cancer Ther. 2009. PMID: 19372546 Free PMC article.

4

Role of heregulin in human cancer.

Breuleux M. Breuleux M. Cell Mol Life Sci. 2007 Sep;64(18):2358-77. doi: 10.1007/s00018-007-7120-0. Cell Mol Life Sci. 2007. PMID: 17530167 Review.

5

Heregulins implicated in cellular functions other than receptor activation.

Breuleux M, Schoumacher F, Rehn D, Küng W, Mueller H, Eppenberger U. Breuleux M, et al. Mol Cancer Res. 2006 Jan;4(1):27-37. doi: 10.1158/1541-7786.MCR-05-0016. Mol Cancer Res. 2006. PMID: 16446404 Free article.

6

Uncertain identity of doxorubicin-resistant MCF-7 cell lines expressing mutated p53.

Pirnia F, Breuleux M, Schneider E, Hochmeister M, Bates SE, Marti A, Hotz MA, Betticher DC, Borner MM. Pirnia F, et al. Among authors: breuleux m. J Natl Cancer Inst. 2000 Sep 20;92(18):1535-6. doi: 10.1093/jnci/92.18.1535. J Natl Cancer Inst. 2000. PMID: 10995814 No abstract available.

7

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study.

Salles G, Schuster SJ, de Vos S, Wagner-Johnston ND, Viardot A, Blum KA, Flowers CR, Jurczak WJ, Flinn IW, Kahl BS, Martin P, Kim Y, Shreay S, Will M, Sorensen B, Breuleux M, Zinzani PL, Gopal AK. Salles G, et al. Among authors: breuleux m. Haematologica. 2017 Apr;102(4):e156-e159. doi: 10.3324/haematol.2016.151738. Epub 2016 Dec 15. Haematologica. 2017. PMID: 27979923 Free PMC article. Clinical Trial. No abstract available.

8

Recombinant adeno-associated viral vectors are deficient in provoking a DNA damage response.

Fragkos M, Breuleux M, Clément N, Beard P. Fragkos M, et al. Among authors: breuleux m. J Virol. 2008 Aug;82(15):7379-87. doi: 10.1128/JVI.00358-08. Epub 2008 May 7. J Virol. 2008. PMID: 18463154 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results